DDAH1 and triple-negative breast carcinoma: ZST316 and ZST152 have been shown in vitro to suppress vasculogenic mimicry, an alternative neo-vascularization pathway driven by iNOS and DDAH1 that increases metastatic potential and adverse outcomes, in triple-negative breast cancer cells [11,16].